These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 35863797)
1. Impact of High Lipoprotein(a) Levels on Clinical Outcomes Following Peripheral Endovascular Therapy. Tomoi Y; Takahara M; Soga Y; Kodama K; Imada K; Hiramori S; Ando K JACC Cardiovasc Interv; 2022 Jul; 15(14):1466-1476. PubMed ID: 35863797 [TBL] [Abstract][Full Text] [Related]
2. Serum Low-Density Lipoprotein Cholesterol Level After Endovascular Therapy in Patients With Claudication. Tomoi Y; Yamaji K; Soga Y; Hiramori S; Ando K J Endovasc Ther; 2019 Jun; 26(3):402-410. PubMed ID: 30873910 [TBL] [Abstract][Full Text] [Related]
3. Association of Serum Lipoprotein (a) With the Requirement for a Peripheral Artery Operation and the Incidence of Major Adverse Cardiovascular Events in People With Peripheral Artery Disease. Golledge J; Rowbotham S; Velu R; Quigley F; Jenkins J; Bourke M; Bourke B; Thanigaimani S; Chan DC; Watts GF J Am Heart Assoc; 2020 Mar; 9(6):e015355. PubMed ID: 32172653 [TBL] [Abstract][Full Text] [Related]
4. Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with peripheral arterial disease. Lee JH; Ko YG; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Jang Y J Vasc Surg; 2016 Mar; 63(3):756-63. PubMed ID: 26603545 [TBL] [Abstract][Full Text] [Related]
5. Association of Statin Therapy With Major Adverse Cardiovascular and Limb Outcomes in Patients With End-stage Kidney Disease and Peripheral Artery Disease Receiving Maintenance Dialysis. Lo HY; Lin YS; Lin DS; Lee JK; Chen WJ JAMA Netw Open; 2022 Sep; 5(9):e2229706. PubMed ID: 36048442 [TBL] [Abstract][Full Text] [Related]
6. Elevated Lp(a) (Lipoprotein[a]) Levels Increase Risk of 30-Day Major Adverse Cardiovascular Events in Patients Following Carotid Endarterectomy. Waissi F; Dekker M; Timmerman N; Hoogeveen RM; van Bennekom J; Dzobo KE; Schnitzler JG; Pasterkamp G; Grobbee DE; de Borst GJ; Stroes ESG; de Kleijn DPV; Kroon J Stroke; 2020 Oct; 51(10):2972-2982. PubMed ID: 32878565 [TBL] [Abstract][Full Text] [Related]
7. Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. Nicholls SJ; Tang WH; Scoffone H; Brennan DM; Hartiala J; Allayee H; Hazen SL J Lipid Res; 2010 Oct; 51(10):3055-61. PubMed ID: 20601648 [TBL] [Abstract][Full Text] [Related]
8. High Apolipoprotein E Levels Predict Adverse Limb Events in Patients with Peripheral Artery Disease Due to Peripheral Artery Disease Undergoing Endovascular Treatment and On-Statin Treatment. Fukase T; Dohi T; Kato Y; Chikata Y; Takahashi N; Endo H; Doi S; Nishiyama H; Okai I; Iwata H; Okazaki S; Isoda K; Miyauchi K; Daida H; Minamino T Int Heart J; 2021 Jul; 62(4):872-878. PubMed ID: 34276016 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients. Kwon SW; Lee BK; Hong BK; Kim JY; Choi EY; Sung JM; Rhee JH; Park YM; Ma DW; Chung H; Mun HS; Lee SJ; Park JK; Min PK; Yoon YW; Rim SJ; Kwon HM Int J Cardiol; 2013 Sep; 167(5):1990-4. PubMed ID: 22633779 [TBL] [Abstract][Full Text] [Related]
10. Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention. Suwa S; Ogita M; Miyauchi K; Sonoda T; Konishi H; Tsuboi S; Wada H; Naito R; Dohi T; Kasai T; Okazaki S; Isoda K; Daida H J Atheroscler Thromb; 2017 Nov; 24(11):1125-1131. PubMed ID: 28321012 [TBL] [Abstract][Full Text] [Related]
15. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2. Natsuaki M; Furukawa Y; Morimoto T; Nakagawa Y; Ono K; Kaburagi S; Inada T; Mitsuoka H; Taniguchi R; Nakano A; Kita T; Sakata R; Kimura T; Circ J; 2012; 76(6):1369-79. PubMed ID: 22447012 [TBL] [Abstract][Full Text] [Related]
16. Circulating malondialdehyde-modified low-density lipoprotein (MDA-LDL) as a novel predictor of clinical outcome after endovascular therapy in patients with peripheral artery disease (PAD). Takamura TA; Tsuchiya T; Oda M; Watanabe M; Saito R; Sato-Ishida R; Akao H; Kawai Y; Kitayama M; Kajinami K Atherosclerosis; 2017 Aug; 263():192-197. PubMed ID: 28651186 [TBL] [Abstract][Full Text] [Related]
17. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Gurdasani D; Sjouke B; Tsimikas S; Hovingh GK; Luben RN; Wainwright NW; Pomilla C; Wareham NJ; Khaw KT; Boekholdt SM; Sandhu MS Arterioscler Thromb Vasc Biol; 2012 Dec; 32(12):3058-65. PubMed ID: 23065826 [TBL] [Abstract][Full Text] [Related]
18. Temporal Changes in Secondary Prevention and Cardiovascular Outcomes After Revascularization for Peripheral Arterial Disease in Denmark: A Nationwide Cohort Study. Søgaard M; Nielsen PB; Skjøth F; Eldrup N; Larsen TB Circulation; 2021 Mar; 143(9):907-920. PubMed ID: 33300375 [TBL] [Abstract][Full Text] [Related]
19. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441 [TBL] [Abstract][Full Text] [Related]